• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Member Resources

Pipelines in Oncology

November 20, 2007 - Supergen

http://www.supergen.com/?main=home

Gavin Choy, PharmD – VP, Clinical Operations
David Bearss, MD – VP, Chief Scientist  

Presentation on:

  • MP470 (Multi-TKI/ Rad51 Suppressor)
  • MP529 (Aurora Inhibitor)
  • S110 (DNMT Inhibitor)


November 15, 2007 - Exelixis, Inc

http://www.exelixis.com

Dana T Aftab, PhD - VP, Translational Research
Art DeCillis, MD - VP, Clinical Research

Presentation on:

  • "Targeting kinase signaling pathways with small molecules for the treatment of cancer"


November 8, 2007 - Threshold Pharmaceuticals

http://www.thresholdpharm.com/

John Curd, MD - President, Chief Medical Officer

Presentation on:

  • Glufosfamide – ifosfamide alkylator/glucose conjugate
  • Hypoxia-Activated Prodrug (Th-302)
  • 2-Deoxyglucose


November 6, 2007 - Nereus Pharmaceuticals

http://www.nereuspharm.com

Matt Spear, MD - Chief Medical Officer, Vice President
Michael Paladino, MD - Chief Technical Officer

Presentation on:

  • NPI-2538 – Vascular Disrupting Agent
  • NPI-0052 – Proteasome Inhibitor


October 18, 2007 - Merck Pharmaceuticals

http://www.merck.com

Stephen Friend, MD - Executive Vice President, Oncology

Presentation on:

  • "Can Pre-clinical Work Impact Clinical Trials?"


October 17, 2007 - Pharmacyclics

http://www.pharmacyclics.com

Sriram Balasubramanian, PhD - Director Translational Research
Markus Renschler, MD, SVP, Oncology Clinical Development

Presentation on:

  • PCI-24781 – HDAC inhibitor
  • PCI-27483 – Factor VIIa inhibitor
  • PCI-32765 – Tyrosine kinase inhibitor


October 11, 2007 - MGI Pharma (PARP Team Only)

http://www.mgipharma.com

Jie Zhang, PhD - Principal Scientist II
Krystyna Wozniak, PhD - Director, Animal Pharmacology
Beth Zaharoff - Senior Medical Science Liaison
Mary Osbakken - President, Osbakken Consulting –Medical Monitor for MGI for PARP Program
Anthony Kiorpes, PhD  - Director of Toxicology

Presentation on: 

  • PARP Inhibitor Program


September 18, 2007 - Bayer Pharmaceuticals

http://www.pharma.bayer.com/en/home.html

Jeffrey S. Humphrey, MD, Vice President, US Medical Sciences, Oncology
Karl-Heinz Thierauch, PhD, Therapeutic Research Oncology, Bayer-Schering

Presentation on:

Clinical:

  • Nexavar® (sorafenib): multi-kinase inhibitor for the treatment of advanced renal cell carcinoma
  • Leukine® (sargramostim): GM-CSF (granulocyte-macrophage colony-stimulating factor) in AML
  • Campath® (alemtuzumab): for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
  • Fludara® (fludarabine phosphate): FLUDARA® (fludarabine phosphate) antineoplastic agent for refractory B-CLL
  • Zevaline® (Ibritumomab Tiuxetan): [90Y]-radiolabelled Zevalin: for adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL).

Pre-clinical:

  • Tocosol (paclitaxel emulsion): under development for treatment of women with metastatic breast cancer
  • Sagopilone (ZK-Epo): in phase 2 development
  • Other pipeline compounds currently in clinical development


September 4, 2007 - MGI Pharma

http://www.mgipharma.com

Michael Cullen Jr, MD - Vice President, Clinical Affairs/ Chief Medical Officer
Beth Zaharoff - Senior Medical Science Liaison

Presentation on:

  • Dacogen - AML
  • Amolimogene – for cervical dysplasia
  • Irofulven – various solid tumors
  • ZYC300 - for solid tumors
  • GCPII - for chemotherapy induced neuropathy
  • PARP inhibitors


June 21, 2007 - Boehringer Ingelheim (Germany)

http://www.boehringer-ingelheim.com/corporate/home/home.asp

Wolfgang Rettich, MD - Senior Vice President Research
Andree Amelsberg, MD, MBA - Executive Director  Oncology
Gerd Stehle, MD - Therapeutic Head Oncology

Presentation on:

  • Overview of Oncology Drug Discovery Research and Clinical Research at Boehringer Ingelheim
  • BIBW 2992 - Dual, Irreversible EGFR/HER2 Inhibitor
  • BIBF 1120 - Triple Angiokinase Inhibitor
  • BI 2536 - First-In-Class Plk1 inhibitor


June 25, 2007 - OSI Pharmaceuticals

http://www.osip.com/

Phil Rutledge, MA, MBA - Director, Medical Sciences Liaison
John Haley, PhD - Senior Research Director, Translational Research

Presentation on:

  • OSI-906 – IGF-1R Inhibitor
  • Tarceva
  • Torc1/ Torc2 Inhibitor


June 11, 2007 - Cyclacel (UK)

http://www.cyclacel.com

Judy Chiao, MD - VP, Clinical Development and Regulatory Affairs
Simon Green, PhD - Team Leader

Presentation on:

  • Seliciclib - oral CDK inhibitor
  • Sapacitabine -oral nucleoside analog
  • CYC116 - oral aurora kinase inhibitor


May 24, 2007 - Biogen Idec

http://www.biogenidec.com/

David R Parkinson, MD - Senior VP, Oncology Research and Development

Presentation on:

  • Rituximab
  • Galiximab - Anti-CD80
  • Lumiliximab - Anti-CD23
  • Volociximab - Anti-alpha5 beta 1
  • Hsp90 inhibitors - BIIB021 and BIIB028
  • Anti-Crypto immunoconjugate


May 17, 2007 - Roche Pharmaceuticals

http://www.roche.com/home.html

David Heimbrook, PhD - VP Nutley Oncology Research and Global Therapy Area Head Oncology
Kapil Dhingra, MD - VP Group Leader Oncology
Catherine Wheeler, MD - Therapeutic Expert for Medical Science - Oncology

Presentation on:

  • Brief Overview Genentech/Roche Relationship
  • Late Stage Compounds (Avastin, Herceptin, Rituxan, Xeloda, Tarceva)
  • Early Stage Compounds:
    • Omnitarg, Epothilones, CDK Inhibitor, MAI (Mitosis-Angiogenesis Inhibitor)
    • Anti-IGFR-1 Antibody, Selective mutant b-raf Inhibitor
    • Glyco-engineered anti-CD20 Antibody
    • MDM2-p53 interaction inhibitor


May 9, 2007 - Protox Therapeutics

http://www.protoxtherapeutics.com/

Fahar Merchant, MD - President and CEO

Presentation on:

  • PRX302 – Engineered version of proaerolysin, a pore-forming protein secreted by the bacteria Aeromonas hydrophilia – localized, recurrent prostate cancer, BPH
  • PRX321 – toxin fusion protein that has been evaluated for the treatment of glioma and in patients with peripheral solid tumors that over-express IL-4 receptors, such as kidney and lung carcinoma


May 7, 2007 - Tigris Pharmaceuticals

http://www.tigrispharma.com/

Binh Nguyen, MD - Vice President of Clinical Development and Operations

Presentation on:

  • Immunomodulator A007 for cervical dysplasia (currently in phase 2),
  • AFP-464 - an  aminoflavone pro-drug (currently in phase 1  -potential indications renal and breast )
  • Two pre-clinical drugs: The Anti-VEGF/PDGF drug GFB204 and The GGTI inhibitor GGTI2418 (solid tumors)


 

 


 

April 17, 2007 - Reata Pharmaceuticals

http://www.reatapharma.com/index.asp

Colin J Meyer, MD, MBA - Director of Product Development
Paul Foster, MD - Chief Medical Officer, VP Clinical Development and Regulatory Affairs
Leslie Lescale-Matys, MD - Director of Clinical Programs

Presentation on:

  • RTA 402 - NF kappa B and STAT3 Inhibitor
  • RTA 744 - Novel Anthracycline derivative (crosses blood-brain barrier)
  • Update on preclinical efforts
  • p53 protein misfolding array


April 4, 2007 - Attenuon LLC

http://www.attenuon.com/

Andrew P Mazar, PhD, Chief Scientific Offocer, Senior Vice President Research and Development
Josh L Distler - Chief Operations Officer, Senior Vice President

Presentation on:

  • ATN-658, Monoclonal antibody specific for the D2D3 domain of uPAR
  • ATN-224, SOD-1 Inhibitor


March 23, 2007 - Progen Ltd (Australia)

http://www.progen.com.au/

Anand Gautam, PhD - Vice President, Research and Development

Presentation on:

  • PI-88 – Anti-angiogenic compound in Phase II for melanoma, prostate, liver and lung cancer
  • PI-166 – for unresectable hepatocellular carcinoma


March 15, 2007 - Infinity Pharmaceuticals

http://ipi.com/

Julian Adams, PhD - President of Research and Development and Chief Scientific Officer
David Grayzel, MD - Vice President, Clinical and Medical Affairs

Presentation on:

  • IPI-504 - Hsp 90 Inihibitor


February 27, 2007 - Astex Therapeutics (UK)

http://www.astex-therapeutics.com/home.php

 Murray Yule, MD - Company Physician 

Presentation on:

  •  AT-7519 - potent cell cycle inhibitor in early clinical development for the treatment of advanced solid tumors and hematologic cancer. The drug targets key cyclin-dependent kinases (CDKs), resulting in tumor shrinkage.
  • AT-9311 - Cyclin-Dependent Kinase Inhibitor


February 15, 2007 - Amgen

http://www.amgen.com

C Glenn Begley, MBBS, PhD - VP, Hematology & Oncology Research
Jan Pinkas, PhD - Senior Scientist, Oncology Research
Douglas Saffran, PhD - Principal Scientist, Oncology Research

Products Presented:

  • Amgen 479 - Anti-CD221 (IFG1-R) Monoclonal Antibody
  • Amgen 706 - Oral, multi-kinase inhibitor, anti-angiogenic
  • Denosumab - Anti-RANKL Monoclonal Antibody


January 23, 2007 - EntreMed (Canada)

http://www.Entremed.com

Mark R Bray, M.Sc, PhD – Senior Director, Preclinical Sciences
Carolyn Sidor, MD, MBA – Vice President, Chief Medical Officer
Theresa LaValle, PhD – Senior Director, Cell Biology

Presentation on:

  • 2-methoxyestradiol (now in several small Phase 2 studies)
  • ENMD-1198 - an analog of 2-methoxyestradiol - now in Phase 1 
  • MKC-1, a cell cycle regulator licensed from Roche now in two Phase 2 studies
  • ENMD981693, an AK/RTK inhibitor


January 18, 2007 - Celgene

http://www.celgene.com

Bob Delap, MD, PhD - Vice President Global Medical Research
Peter Schafer, MD - Director of Biology

Presentation on:

  • IMIDS (Immunomodulatory Drugs):
    • Panmilomide (formerly Actimid, CC-4047)
    • Revlimid (Lenalidomide)
  • SelCIDS (Selective Cytokine Inhibitory Drugs):
    • JNK-2 Inhibitors


January 9, 2007 - PTC Therapeutics

http://www.ptcbio.com

Langdon Miller, MD – Chief Medical Officer
Samit Hirawat, MD – Senior Director, Clinical Development 

Presentation on:

  • PTC-124 - novel, orally administered small-molecule compound that targets a particular genetic alteration known as a nonsense mutation
  • PTC-299 - novel, orally administered small-molecule compound designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors